Clinical Trial Update: The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) [Phase 2]

View source ↗

Summary

Milestone's Phase 2 pediatric study evaluates Etripamil nasal spray for paroxysmal supraventricular tachycardia and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Supraventricular Tachycardia

Drugs mentioned

• etripamil nasal spray (etripamil)

Snippet

Sponsor: Milestone Pharmaceuticals Inc. | Conditions: Paroxysmal Supraventricular Tachycardia | Phase 2 | Status: RECRUITING